Single Dose PG102 in Patients With Active Psoriatic Arthritis
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety and tolerability of a single intravenous dose
of PG102 in patients with psoriatic arthritis. The secondary objectives are to evaluate how
PG102 moves around the body and to explore its effects on the disease.